Ipatasertib dihydrochloride (formerly also called GDC-0068) is a novel, potent, orally bioavailable, ATP-competitive and highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, it showed 620-fold selectivity over PKA.

TIC10 (ONC-201, NSC-350625), an imipridone compound, is a novel, potent, orally bioavailable, brain/BBB penetrant, and stable tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) inducer with potential anticancer activity.

Miransertib HCl (formerly known as ARQ-092; MK7075), the HCl salt of Miransertib, is a novel, orally bioactive and selective allosteric inhibitor of AKT anticancer activity.

PHT-427 (CS0223) is a novel, potent, orally bioactive and dual inhibitor of Akt and PDPK1 (PtdIns dependent protein kinase-1) with potential anticancer activity.

CTX-0294885 is a novel potent and broad-spectrum kinase inhibitor and a sepharose-supported kinase capture reagent which exhibits inhibitory activity against a broad range of kinases in vitro.

Uprosertib (formerly known as GSK2141795 and GSK795), an analog of GSK2110183, is a potent, orally bioavailable and ATP-competitive Akt inhibitor with IC50 values of 180 nM, 328 nM, and 38 nM for Akt1/Akt2/Akt3, respectively.

SC66 is a novel, potent and allosteric inhibitor of AKT with potential anticancer activity, it reduces cell viability in a dose- and time-dependent manner, inhibits colony formation and induces apoptosis in hepatocellular carcinoma (HCC) cells.

AT7867 is a novel, highly potent, orally bioavailable and ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA (protein kinase A) with potential anticancer activity.

Crebanine is a novel and potent bioactive compound.

Afuresertib HCl (also named as GSK2110183 HCl) is a potent, orally bioavailable and ATP-competitive Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively.